VERTEX PHARMACEUTICALS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 402.5 USD | +0.35% |
|
+1.59% | -1.08% |
| May. 06 | Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase | MT |
| May. 06 | Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-05-15
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
402.5
USD
Average target price
460.2
USD
Spread / Average Target
+14.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.08% | 104B | |
| +9.15% | 106B | |
| +6.90% | 23.25B | |
| -11.55% | 22.5B | |
| -7.22% | 18.7B | |
| -37.08% | 17.95B | |
| -9.91% | 16.99B | |
| +7.55% | 14.26B | |
| +40.04% | 12.76B | |
| +320.26% | 8.62B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Says Health Canada Gives Marketing Authorization to Expand Use of Kalydeco to Treat Cystic Fibrosis